Watching Shares Of Aptevo Therapeutics; Traders Circulating Zacks Investment Research Article Titled, "Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know"; Shares Seeing Volume
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics (APVO) has been upgraded to a 'Buy' rating by Zacks Investment Research. This news has led to increased trading volume in APVO shares.
August 15, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptevo Therapeutics (APVO) has been upgraded to a 'Buy' rating by Zacks Investment Research, resulting in increased trading volume.
The upgrade to a 'Buy' rating by a reputable research firm like Zacks Investment Research is likely to positively impact APVO's stock price in the short term. The increased trading volume indicates heightened investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100